NASDAQ:PGNY

Progyny (PGNY) Stock Forecast, Price & News

$34.35

-0.04 (-0.12%)

(As of 01:51 PM ET)

Compare

Today's Range: $34.04
▼
$34.98
50-Day Range: $33.09
▼
$42.90
52-Week Range: $28.03
▼
$45.98

Volume: 281,184 shs
Average Volume: 818,048 shs
Market Capitalization: $3.28 billion

P/E Ratio: 70.10
Dividend Yield: N/A
Price Target: $48.67

Progyny MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 41.4% Upside
$48.67 Price Target
Short Interest: Bearish
6.61% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.12
Based on 9 Articles This Week
Insider Trading: Selling Shares
$122.85 M Sold Last Quarter
Proj. Earnings Growth: 25.93%
From $0.54 to $0.68 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.03 out of 5 stars

Medical Sector

28th out of 971 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

1st out of 7 stocks

4.4

Analyst's Opinion

Consensus Rating
Progyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $48.67, Progyny has a forecasted upside of 41.4% from its current price of $34.42.
Amount of Analyst Coverage
Progyny has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
6.61% of the float of Progyny has been sold short.
Short Interest Ratio / Days to Cover
Progyny has a short interest ratio ("days to cover") of 8.
Change versus previous month
Short interest in Progyny has recently increased by 0.74%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Progyny does not currently pay a dividend.
Dividend Growth
Progyny does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PGNY.

3.4

News and Social Media Coverage

News Sentiment
Progyny has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Progyny this week, compared to 3 articles on an average week.
Search Interest
Only 7 people have searched for PGNY on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.
MarketBeat Follows
9 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $122,853,509.00 in company stock.
Percentage Held by Insiders
14.30% of the stock of Progyny is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Progyny are expected to grow by 25.93% in the coming year, from $0.54 to $0.68 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Progyny is 70.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.57.
Price to Earnings Ratio vs. Sector
The P/E ratio of Progyny is 70.24, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 106.05.
Price to Earnings Growth Ratio
Progyny has a PEG Ratio of 1.54. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Progyny has a P/B Ratio of 8.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Progyny (NASDAQ:PGNY) Stock

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

PGNY Price History

30 days | 90 days | 365 days | Advanced Chart

PGNY Stock News Headlines

September 28, 2023 | nasdaq.com

Canaccord Genuity Initiates Coverage of Progyny (PGNY) with Buy Recommendation

September 27, 2023 | finance.yahoo.com

Progyny (PGNY): Unveiling Its True Value

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!

September 13, 2023 | benzinga.com

Check Out What Whales Are Doing With PGNY

September 1, 2023 | finance.yahoo.com

3 Reasons Growth Investors Will Love Progyny (PGNY)

August 29, 2023 | msn.com

Wall Street Loves These 3 Growth Stocks; Should You?

August 22, 2023 | finance.yahoo.com

Progyny Celebrates More Than 30,000 Amazonians Supported on Their Family Building Journeys

August 21, 2023 | seekingalpha.com

Progyny: Strong Secular Tailwind, Great Performance, Recommend Long

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

August 16, 2023 | finance.yahoo.com

Here is Why Growth Investors Should Buy Progyny (PGNY) Now

August 16, 2023 | finance.yahoo.com

Here’s Why Progyny (PGNY) Outperformed in Q2

August 11, 2023 | finance.yahoo.com

Progyny (PGNY) Upgraded to Buy: What Does It Mean for the Stock?

August 10, 2023 | finance.yahoo.com

TPG GP A, LLC Reduces Stake in Progyny Inc

August 7, 2023 | bizjournals.com

Fertility benefits management company Progyny expands to offer menopause care

August 7, 2023 | markets.businessinsider.com

Truist Financial Sticks to Their Buy Rating for Progyny (PGNY)

August 5, 2023 | finance.yahoo.com

Is There Now An Opportunity In Progyny, Inc. (NASDAQ:PGNY)?

August 4, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Progyny

August 4, 2023 | finance.yahoo.com

Progyny Unveils Nationwide Access to Menopause Care

August 4, 2023 | finance.yahoo.com

Compared to Estimates, Progyny (PGNY) Q2 Earnings: A Look at Key Metrics

August 3, 2023 | finance.yahoo.com

Progyny, Inc. Announces Second Quarter 2023 Results

August 3, 2023 | finance.yahoo.com

Progyny (PGNY) Beats Q2 Earnings and Revenue Estimates

July 26, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Boston Scientific (BSX), Teladoc (TDOC) and Progyny (PGNY)

July 20, 2023 | finance.yahoo.com

Progyny, Inc. Announces Details for Its Second Quarter 2023 Results Report

July 19, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Progyny (PGNY)

July 18, 2023 | finance.yahoo.com

Progyny (NASDAQ:PGNY) grows 4.8% this week, taking three-year gains to 54%

July 7, 2023 | msn.com

What Makes Progyny (PGNY) a New Buy Stock

June 29, 2023 | finance.yahoo.com

Quantum Health Partners With Progyny To Launch New Family-Building Benefits Offering

See More Headlines

Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

PGNY Company Calendar

Last Earnings: 8/03/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Miscellaneous health & allied services, not elsewhere classified
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PGNY
CUSIP: N/A
CIK: 1551306
Web: www.progyny.com
Phone: 212-888-3124
Fax: N/A
Employees: 393
Year Founded: 2008

Price Target and Rating

Average Stock Price Forecast: $48.67
High Stock Price Forecast: $62.00
Low Stock Price Forecast: $34.00
Forecasted Upside/Downside: +41.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.49
Trailing P/E Ratio: 70.18
Forward P/E Ratio: 63.69
P/E Growth: 1.52
Net Income: $30.36 million
Net Margins: 5.15%
Pretax Margin: 5.14%
Return on Equity: 12.19%
Return on Assets: 8.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.89
Quick Ratio: 2.89

Sales & Book Value

Annual Sales: $786.91 million
Price / Sales: 4.17
Cash Flow: $0.35 per share
Price / Cash Flow: 99.43
Book Value: $4.06 per share
Price / Book: 8.47

Miscellaneous

Outstanding Shares: 95,410,000
Free Float: 81,763,000
Market Cap: $3.28 billion
Optionable: Not Optionable
Beta: 1.51

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. David J. Schlanger (Age 64)
Exec. Chairman
Comp: $510.41k

Mr. Peter Anevski (Age 56)
CEO & Director
Comp: $1.01M

Mr. Michael Sturmer (Age 46)
Pres
Comp: $761.5k

Mr. Mark S. Livingston (Age 57)
Chief Financial Officer
Comp: $693.87k

Ms. Allison Swartz (Age 33)
Exec. VP, Gen. Counsel & Sec.
Comp: $173.35k

Mr. James Hart
VP of Investor Relations

Ms. Risa Fisher
Exec. VP & Chief Marketing Officer

Ms. Cassandra Pratt
Sr. VP of People

Ms. Julie Stadlbauer
Exec. VP of Strategic Sales & Partnerships

Ms. Janet Choi M.D.
Member of the Medical Advisory Board & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PGNY Stock - Frequently Asked Questions

Should I buy or sell Progyny stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PGNY shares.
View PGNY analyst ratings or view top-rated stocks.
What is Progyny's stock price forecast for 2023?: 8 equities research analysts have issued 12-month price targets for Progyny's stock. Their PGNY share price forecasts range from $34.00 to $62.00. On average, they predict the company's stock price to reach $48.67 in the next year. This suggests a possible upside of 41.5% from the stock's current price.
View analysts price targets for PGNY or view top-rated stocks among Wall Street analysts.
How have PGNY shares performed in 2023?: Progyny's stock was trading at $31.15 at the start of the year. Since then, PGNY stock has increased by 10.4% and is now trading at $34.39.
View the best growth stocks for 2023 here.
When is Progyny's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PGNY earnings forecast.
How were Progyny's earnings last quarter?: Progyny, Inc. (NASDAQ:PGNY) announced its quarterly earnings results on Thursday, August, 3rd. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.10 by $0.05. The firm earned $279.40 million during the quarter, compared to the consensus estimate of $261.91 million. Progyny had a trailing twelve-month return on equity of 12.19% and a net margin of 5.15%. Progyny's quarterly revenue was up 43.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.09 earnings per share.
What ETFs hold Progyny's stock?: ETFs with the largest weight of Progyny (NASDAQ:PGNY) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), Aztlan Global Stock Selection DM SMID ETF (AZTD), BNY Mellon Women's Opportunities ETF (BKWO), SPDR S&P Health Care Services ETF (XHS), Thrivent Small-Mid Cap ESG ETF (TSME), Harbor Corporate Culture Small Cap ETF (HAPS), Nuveen Small Cap Select ETF (NSCS) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).
What guidance has Progyny issued on next quarter's earnings?: Progyny updated its FY23 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of $0.50-$0.53 for the period, compared to the consensus earnings per share estimate of $0.47. The company issued revenue guidance of $1.075-$1.09 billion, compared to the consensus revenue estimate of $1.06 billion.
What is David Schlanger's approval rating as Progyny's CEO?: 25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Progyny own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD).
When did Progyny IPO?: (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.
What is Progyny's stock symbol?: Progyny trades on the NASDAQ under the ticker symbol "PGNY."
How do I buy shares of Progyny?: Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Progyny's stock price today?: One share of PGNY stock can currently be purchased for approximately $34.39.
How much money does Progyny make?: Progyny (NASDAQ:PGNY) has a market capitalization of $3.28 billion and generates $786.91 million in revenue each year. The company earns $30.36 million in net income (profit) each year or $0.49 on an earnings per share basis.
How many employees does Progyny have?: The company employs 393 workers across the globe.
How can I contact Progyny?: Progyny's mailing address is 1359 BROADWAY, NEW YORK NY, 10018. The official website for the company is www.progyny.com. The company can be reached via phone at 212-888-3124 or via email at investors@progyny.com.

This page (NASDAQ:PGNY) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial